Literature DB >> 15676005

Successful reversal of resistent hypodynamic septic shock with levosimendan.

M Matejovic, A Krouzecky, J Radej, I Novak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15676005     DOI： 10.1111/j.1399-6576.2005.00541.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN： 0001-5172            Impact factor:   2.105


× No keyword cloud information.
  12 in total

1.  Levosimendan in septic shock: another piece in the puzzle, but many pieces are still lacking.

Authors:  Daniel De Backer; Fabio Silvio Taccone; Peter Radermacher
Journal:  Intensive Care Med       Date:  2007-01-30       Impact factor: 17.440

2.  Cardioprotective and functional effects of levosimendan and milrinone in mice with cecal ligation and puncture-induced sepsis.

Authors:  Shigeyuki Yamashita; Tokiko Suzuki; Keisuke Iguchi; Takuya Sakamoto; Kengo Tomita; Hiroki Yokoo; Mari Sakai; Hiroki Misawa; Kohshi Hattori; Toshi Nagata; Yasuhide Watanabe; Naoyuki Matsuda; Naoki Yoshimura; Yuichi Hattori
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-20       Impact factor: 3.000

Review 3.  Recent advances in sepsis and septic shock.

Authors:  Praveen Khilnani; Satish Deopujari; Joe Carcillo
Journal:  Indian J Pediatr       Date:  2008-09-04       Impact factor: 1.967

4.  Diastolic dysfunction and heart failure with a preserved ejection fraction: Relevance in critical illness and anaesthesia.

Authors:  R Maharaj
Journal:  J Saudi Heart Assoc       Date:  2012-02-01

5.  Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine.

Authors:  Joe Brierley; Joseph A Carcillo; Karen Choong; Tim Cornell; Allan Decaen; Andreas Deymann; Allan Doctor; Alan Davis; John Duff; Marc-Andre Dugas; Alan Duncan; Barry Evans; Jonathan Feldman; Kathryn Felmet; Gene Fisher; Lorry Frankel; Howard Jeffries; Bruce Greenwald; Juan Gutierrez; Mark Hall; Yong Y Han; James Hanson; Jan Hazelzet; Lynn Hernan; Jane Kiff; Niranjan Kissoon; Alexander Kon; Jose Irazuzta; Jose Irazusta; John Lin; Angie Lorts; Michelle Mariscalco; Renuka Mehta; Simon Nadel; Trung Nguyen; Carol Nicholson; Mark Peters; Regina Okhuysen-Cawley; Tom Poulton; Monica Relves; Agustin Rodriguez; Ranna Rozenfeld; Eduardo Schnitzler; Tom Shanley; Saraswati Kache; Sara Skache; Peter Skippen; Adalberto Torres; Bettina von Dessauer; Jacki Weingarten; Timothy Yeh; Arno Zaritsky; Bonnie Stojadinovic; Jerry Zimmerman; Aaron Zuckerberg
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

Review 6.  Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

Authors:  Daniel De Backer
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

7.  Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study.

Authors:  Andrea Morelli; Abele Donati; Christian Ertmer; Sebastian Rehberg; Matthias Lange; Alessandra Orecchioni; Valeria Cecchini; Giovanni Landoni; Paolo Pelaia; Paolo Pietropaoli; Hugo Van Aken; Jean-Louis Teboul; Can Ince; Martin Westphal
Journal:  Crit Care       Date:  2010-12-23       Impact factor: 9.097

Review 8.  Sepsis-induced cardiomyopathy.

Authors:  Francisco J Romero-Bermejo; Manuel Ruiz-Bailen; Julian Gil-Cebrian; Maria J Huertos-Ranchal
Journal:  Curr Cardiol Rev       Date:  2011-08

9.  An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial.

Authors:  Robert M L'E Orme; Gavin D Perkins; Daniel F McAuley; Kathleen D Liu; Alexina J Mason; Andrea Morelli; Mervyn Singer; Deborah Ashby; Anthony C Gordon
Journal:  Trials       Date:  2014-06-02       Impact factor: 2.279

10.  Levosimendan Versus Dobutamine in Myocardial Injury Patients with Septic Shock: A Randomized Controlled Trial.

Authors:  Jianb-biao Meng; Ma-hong Hu; Zhi-zhen Lai; Chun-lian Ji; Xiu-juan Xu; Geng Zhang; Shuyuan Tian
Journal:  Med Sci Monit       Date:  2016-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.